Top news of the week: 23.09.2021.
Career And Jobs
BioSpace Movers & Shakers, Sept. 17
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Investment in Biopharma is Reaching an Inflection Point
In recent years, fundraising and investment in biotechnology have reached record levels.
Who are the women supercharging biopharma R&D? Nominate them for this year's special report
The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech ...
The FDA objects to biotech billionaire Bob Duggan’s PhIII plans — and he’s not budging
Summit Therapeutics, the Cambridge, MA-based biotech run by billionaire investor Bob Duggan, has found itself in the FDA’s crosshairs. Last month, Summit announced its intent to combine two ...
NC Fought Hard for Gilead’s New Site, Adding to Exploding Biotech Presence
Gilead announced its plans to replant some roots back in North Carolina’s Research Triangle. The new site is expected to bring in 275 jobs to the North Hills innovation district.
Novartis doesn't think optogenetics will completely cure blindness—but its new biotech is going to give it a try
Novartis already bought into optogenetic gene therapy technology last year, but the Swiss Pharma wants more. Enter Arctos Medical, which will now join Novartis with its gene therapy program ...
Novartis veteran Barth takes the helm at autoimmune biotech MiroBio
As MiroBio gears up for its first clinical trial, the autoimmune biotech is getting a new CEO: Carolin Barth, M.D., joins after a 17-year run at Novartis, where she most recently led ...
So what happened with Novartis Gene Therapies? Here's your answer
Over the last couple of days it’s become clear that the gene therapy division at Novartis has quietly undergone a major reorganization. We learned on Monday that Dave Lennon, who had ...